Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health to Sell 3 Million Shares

NEW YORK (GenomeWeb News) - Genomic Health plans to sell 3 million shares of its common stock through an underwritten public offering, the company said yesterday.
 
The company said it will use the proceeds from the sale for general corporate purposes, marketing, R&D, and for expanding its labs.
 
Genomic Health said it will grant underwriters a 30-day option to buy an additional 450,000 shares.
 
The company's stock closed at $15.79 on Monday.
 
J.P. Morgan Securities will be sole book-runner for the offering, and Lehman Brothers, Piper Jaffray, and JMP securities will be co-managers.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.